Research ArticleDrug Discovery and Translational Medicine
Sembragiline: a novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer’s disease
Edilio Borroni, Bernd Bohrmann, Fiona Grueninger, Eric Prinssen, Stephane Nave, Hansruedi Loetscher, Shankar J Chinta, Subramanian Rajagopalan, Anand Rane, Almas Siddiqui, Bart Ellenbroek, Juerg Messer, Axel Pahler, Julie K Anderson, Rene Wyler and Andrea M Cesura
Journal of Pharmacology and Experimental Therapeutics June 22, 2017, jpet.117.241653; DOI: https://doi.org/10.1124/jpet.117.241653
Edilio Borroni
1 Hoffmann-La Roche Ltd;
Bernd Bohrmann
2 F. Hoffmann-La Roche Ltd;
Fiona Grueninger
2 F. Hoffmann-La Roche Ltd;
Eric Prinssen
2 F. Hoffmann-La Roche Ltd;
Stephane Nave
2 F. Hoffmann-La Roche Ltd;
Hansruedi Loetscher
2 F. Hoffmann-La Roche Ltd;
Shankar J Chinta
3 Buck Institute for Research on Aging;
Subramanian Rajagopalan
3 Buck Institute for Research on Aging;
Anand Rane
3 Buck Institute for Research on Aging;
Almas Siddiqui
3 Buck Institute for Research on Aging;
Bart Ellenbroek
4 Evotec International GmbH
Juerg Messer
2 F. Hoffmann-La Roche Ltd;
Axel Pahler
2 F. Hoffmann-La Roche Ltd;
Julie K Anderson
3 Buck Institute for Research on Aging;
Rene Wyler
2 F. Hoffmann-La Roche Ltd;
Andrea M Cesura
4 Evotec International GmbH
Data Supplement
- Supplemental Data -
Supplemental methods, 3 tables, and 2 figures.